AKIGAI featured in one of Europe’s largest Biotech outlet!
"AKIGAI, a Norway-based company, is hoping to change the narrative in neuropathic pain with EGFR inhibitors."
AKIGAI founders featured in Norway’s national newspapers
Serendipity, clinical acumen and relentless follow-up. Driven by dramatic patient experiences.
AKIGAI-gründerne oversvømmes av henvendelser fra leger og pasienter
"We want to signal hope and need to focus on developing our solution for all patients."
AKIGAI amongst the most advanced Biotechs in Norway
AKIGAI is pivotal ready for phase III study in CRPS
AKIGAI CEO left oncology clinic to serve millions of pain patients
We have promised to bring this solution to all neuropathic pain patients
AKIGAI Welcomes Strategic Investment Partner!
AKIGAI has secured a strategic partnership with investor Brynjar Forbergskog
FDA grants Orphan Designation for the treatment of CRPS with AKI-007
Dramatic, durable and safe pain relief in chronic CRPS patients has lead to this milestone. A phase III trial is the next step.
Orphan Designation
AKIGAI is excited that we were granted an Orphan Designation from the EMA for the treatment of CRPS with our 1st generation EGFR inhibitor tablet.